WeVote
Log In

Bill

Bill

HD 2903

An Act relative to capping the price of epinephrine

194th Legislature (2025-2026) Introduced by Marjorie Decker

Massachusetts bill caps epinephrine prices to improve affordability and emergency medication access for allergy and anaphylaxis patients.

0
WeVote Research Nonpartisan
Bill Summary · HD 2903

Legislative bill overview

HD 2903 would establish a price cap on epinephrine, a life-saving medication used to treat severe allergic reactions and anaphylaxis. The bill aims to make this critical medication more affordable and accessible by limiting how much manufacturers and sellers can charge for epinephrine products, particularly auto-injectors like EpiPens.

Why is this important

Epinephrine is an essential medication with no substitute for anaphylaxis treatment, making price controls a matter of public health and potentially life-or-death accessibility. The dramatic price increases of epinephrine auto-injectors over the past decade have made this medication unaffordable for many patients, even with insurance, creating barriers to carrying necessary emergency medication.

Potential points of contention

  • Market effects: Critics argue price caps could discourage pharmaceutical manufacturers from producing or investing in epinephrine products, potentially creating shortages or reducing innovation in delivery mechanisms
  • Implementation challenges: Defining an appropriate price cap is complex—too low and manufacturers may exit the market; too high and affordability goals aren't met
  • Scope questions: The bill's specific pricing thresholds, applicability to generic versus brand-name versions, and whether it covers all epinephrine formulations would significantly affect its real-world impact

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.